Is MetaVia Inc. (MTVA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.6% / 30% | 311.7% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 2.6% / 33% | 311.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.8% / 33% | 98.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.6% / 33% | 311.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.8% / 33% | 98.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -195.6% | |
| Return on Assets (ROA) | -62.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$25M |
| Free Cash Flow | -$25M |
| Total Debt | $136,000 |
| Debt-to-Equity | 3.9 |
| Current Ratio | 1.9 |
| Total Assets | $16M |
Price & Trading
| Last Close | $1.32 |
| 50-Day MA | $1.85 |
| 200-Day MA | $6.97 |
| Avg Volume | 249K |
|
52-Week Range
$1.21
| |
About MetaVia Inc. (MTVA)
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MetaVia Inc. (MTVA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MetaVia Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MetaVia Inc.'s debt ratio?
MetaVia Inc.'s debt ratio is 2.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.8%.
What are MetaVia Inc.'s key financial metrics?
MetaVia Inc. has a market capitalization of $6M. Return on equity stands at -195.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.